Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management

Br J Haematol. 2018 Jan;180(1):164-166. doi: 10.1111/bjh.14302. Epub 2016 Aug 18.

Authors

David J Iberri^{1

2}, Bernice Y Kwong³, Laurel A Stevens³, Steven E Coutre¹, Jinah Kim⁴, Jean M Sabile², Ranjana H Advani²

Affiliations

¹ Department of Medicine, Division of Hematology, Stanford University, Stanford, CA.
² Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
³ Department of Dermatology, Stanford University, Stanford, CA.
⁴ Department of Pathology, Stanford University, Stanford, CA.

PMID: 27539794
DOI: 10.1111/bjh.14302

No abstract available

Keywords: ibrutinib; new leukaemia drugs; new lymphoma drugs; skin toxicity.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Biopsy
Disease Management
Exanthema / diagnosis*
Exanthema / etiology*
Exanthema / therapy
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Piperidines
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / adverse effects*
Pyrazoles / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
Severity of Illness Index
Symptom Assessment

Substances

Antineoplastic Agents
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Adenine